EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Replacing Alteplase with Tenecteplase: Is the Time Ripe?

Nishita Singh, Bijoy K Menon, Adam A Dmytriw, Robert W Regenhardt, Joshua A Hirsch, Aravind Ganesh

Journal of Stroke · 31.01.2023 · 25 (1) · 72-80

DOI: 10.5853/jos.2022.02880 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Stroke, erschienen am 31.01.2023. Verfasst von Nishita Singh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Calgary Stroke Program, Departments of Clinical Neurosciences, Radiology, and Community Health Sciences, and the Hotchkiss Brain Institute, Universit…. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thrombolysis for acute ischemic stroke has predominantly been with alteplase for over a quarter of a century. In recent years, with trials showing evidence of higher rates of successful reperfusion, similar safety profile and efficacy of tenecteplase (TNK) as compared to alteplase, TNK has now emerged as another potential choice for thrombolysis in acute ischemic stroke. In this review, we will focus on these recent advances, aiming: (1) to provide a brief overview of thrombolysis in stroke; (2) to provide comparisons between alteplase and TNK for clinical, imaging, and safety outcomes; (3) to focus on key subgroups of interest to understand if there is an advantage of using TNK over alteplase or vice-versa, to review available evidence on role of TNK in intra-arterial thrombolysis, as bridging therapy and in mobile stroke units; and (4) to summarize what to expect in the near future from recently completed trials and propose areas for future research on this evolving topic. We present compelling data from several trials regarding the safety and efficacy of TNK in acute ischemic stroke along with completed yet unpublished trials that will help provide insight into these unanswered questions.

Schlagwörter

Stichwörter der Autor:innen

Acute ischemic strokeAlteplaseTenecteplaseThrombolysis

Autor:innen und Institutionen

  • Calgary Stroke Program, Departments of Clinical Neurosciences, Radiology, and Community Health Sciences, and the Hotchkiss Brain Institute, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.
  • Department of Internal Medicine-Neurology Division, Health Sciences Center, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
  • Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Neuroendovascular Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Zitieren

APA

Singh, N., Menon, B. K., Dmytriw, A. A., Regenhardt, R. W., Hirsch, J. A., & Ganesh, A. (2023). Replacing Alteplase with Tenecteplase: Is the Time Ripe?. Journal of Stroke, 25(1), 72-80. https://doi.org/10.5853/jos.2022.02880

Vancouver

Singh N, Menon BK, Dmytriw AA, Regenhardt RW, Hirsch JA, Ganesh A. Replacing Alteplase with Tenecteplase: Is the Time Ripe?. Journal of Stroke. 2023;25(1):72-80. doi:10.5853/jos.2022.02880

BibTeX
@article{Singh2023,
  author = {Singh, Nishita and Menon, Bijoy K and Dmytriw, Adam A and Regenhardt, Robert W and Hirsch, Joshua A and Ganesh, Aravind},
  title = {Replacing Alteplase with Tenecteplase: Is the Time Ripe?},
  journal = {Journal of Stroke},
  year = {2023},
  volume = {25},
  number = {1},
  pages = {72--80},
  doi = {10.5853/jos.2022.02880}
}
Kostenlos starten →